Home > Chemotherapeutics > Casanova
RECLAIMING LIFE FROM PROSTATE CANCER
Bicalutamide
Class
Non-steroidal anti-androgens receptor inhibitor.
MOA
Casonova is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When Casonova is combined with LHRH analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected.
Indications
Use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.
SIDE EFFECTS
Adverse reactions that occurred in more than 10% of patients receiving Bicalutamide plus an LHRH-A were:
- Hot flashes
- Pain (including general, back, pelvic and abdominal)
- Asthenia
- Constipation
- Peripheral edema
- Diarrhea
- Hematuria
- Nocturia
- Anemia
- Infection
- Dyspnea
- Nausea
DOSE
The recommended dose for CASANOVA therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
Pack Size
28’s
Storage
25°-30° C
Available Strength
50mg
